贝伐珠单抗联合新辅助化疗治疗乳腺癌的临床疗效及其对血管内皮生长因子、乳腺组织凋亡分子表达的影响

Clinical efficacy and impact on the expression of vascular endothelial growth factor and apoptosis molecules in breast tissue of bevacizumab combined with neoadjuvant chemotherapy in the treatment of breast cancer

目的探讨贝伐珠单抗联合新辅助化疗治疗乳腺癌的临床疗效及其对血管内皮生长因子、乳腺组织凋亡分子表达的影响。方法选取鄂州市中医医院2017年1月—2019年1月收治的乳腺癌患者128例,按照随机数字表法分为对照组与观察组,每组64例。对照组予以新辅助化疗,观察组在对照组基础上加用贝伐珠单抗治疗。比较2组临床疗效,治疗前后血清血管内皮生长因子VEGF-165、VEGF-121、VEGF-145及乳腺组织凋亡相关分子[捕获受体3(DcR3)、livin、Survivin、XIAP]的表达水平,并观察2组毒副作用发生情况。结果观察组临床疗效优于对照组(P<0.05)。治疗前2组血清VEGF-165、VEGF-121、VEGF-145水平比较,差异无统计学意义(P>0.05);治疗后观察组血清VEGF-165、VEGF-121、VEGF-145水平低于对照组(P<0.05)。治疗前2组DcR3、livin、Survivin、XIAP水平比较,差异无统计学意义(P>0.05);治疗后观察组DcR3、livin、Survivin、XIAP水平低于对照组(P<0.05)。2组肝肾功能损伤、高血压、恶心呕吐、红细胞减少、白细胞减少发生率比较,差异无统计学意义(P>0.05)。结论贝伐珠单抗联合新辅助化疗治疗乳腺癌的临床疗效确切,可有效降低血管内皮生长因子、乳腺组织凋亡分子的表达,且安全性较高。

Objective To investigate the clinical efficacy and impact on the expression of vascular endothelial growth factor and apoptosis molecules in breast tissue of bevacizumab combined with neoadjuvant chemotherapy in the treatment of breast cancer.Methods A total of 128 cases of patients with breast cancer were selected from January 2017 to January 2019 in Ezhou Hospital of Traditional Chinese Medicine,which were divided into control group and observation group according to the random number table method,with 64 cases in each group.The control group was given neoadjuvant chemotherapy,the observation group was treated with bevacizumab on the basis of the control group.Clinical efficacy,the expression levels of serum vascular endothelial growth factors VEGF-165,VEGF-121,VEGF-145 and apoptosis-related molecules in breast tissue(DcR3,livin,Survivin,XIAP) before and after treatment were compared between the two groups,the side effects of the two groups were observed.Results The clinical efficacy of the observation group was better than control group(P<0.05).Before treatment,there was no significant difference in serum VEGF-165,VEGF-121 and VEGF-145 between the two groups(P>0.05);after treatment,the levels of serum VEGF-165,VEGF-121 and VEGF-145 in observation group were lower than control group(P<0.05).Before treatment,there was no significant difference in DcR3,livin,Survivin and XIAP levels between the two groups(P>0.05);after treatment,the levels of DcR3,livin,Survivin and XIAP in observation group were lower than control group(P<0.05).There was no significant difference in the incidence of liver and kidney dysfunction,hypertension,nausea and vomiting,erythropenia and leukopenia between the two groups(P>0.05).Conclusion Bevacizumab combined with neoadjuvant chemotherapy have an exact clinical effect for breast cancer,which can effectively reduce the expression of vascular endothelial growth factor and apoptosis molecules in breast tissue,and with high safety.